<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1995-11-01" modified="2017-05-10" version="186">
<accession>P42336</accession>
<accession>Q14CW1</accession>
<accession>Q99762</accession>
<name>PK3CA_HUMAN</name>
<protein>
<recommendedName>
<fullName>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform</fullName>
<shortName>PI3-kinase subunit alpha</shortName>
<shortName>PI3K-alpha</shortName>
<shortName>PI3Kalpha</shortName>
<shortName>PtdIns-3-kinase subunit alpha</shortName>
<ecNumber evidence="20">2.7.1.153</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha</fullName>
<shortName>PtdIns-3-kinase subunit p110-alpha</shortName>
<shortName>p110alpha</shortName>
</alternativeName>
<alternativeName>
<fullName>Phosphoinositide-3-kinase catalytic alpha polypeptide</fullName>
</alternativeName>
<alternativeName>
<fullName>Serine/threonine protein kinase PIK3CA</fullName>
<ecNumber evidence="20">2.7.11.1</ecNumber>
</alternativeName>
</protein>
<gene>
<name type="primary">PIK3CA</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1994" name="Genomics" volume="24" first="472" last="477">
<title>Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene.</title>
<authorList>
<person name="Volinia S."/>
<person name="Hiles I."/>
<person name="Ormondroyd E."/>
<person name="Nizetic D."/>
<person name="Antonacci R."/>
<person name="Rocchi M."/>
<person name="Waterfield M."/>
</authorList>
<dbReference type="PubMed" id="7713498"/>
<dbReference type="DOI" id="10.1006/geno.1994.1655"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
<scope>VARIANTS VAL-43 AND ARG-332</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1997" name="Bioorg. Med. Chem." volume="5" first="65" last="74">
<title>Cloning and mutagenesis of the p110 alpha subunit of human phosphoinositide 3'-hydroxykinase.</title>
<authorList>
<person name="Stirdivant S.M."/>
<person name="Ahern J."/>
<person name="Conroy R.R."/>
<person name="Barnett S.F."/>
<person name="Ledder L.M."/>
<person name="Oliff A."/>
<person name="Heimbrook D.C."/>
</authorList>
<dbReference type="PubMed" id="9043658"/>
<dbReference type="DOI" id="10.1016/S0968-0896(96)00196-4"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
</reference>
<reference key="3">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
<source>
<tissue>Lung</tissue>
</source>
</reference>
<reference key="4">
<citation type="journal article" date="1999" name="Oncogene" volume="18" first="4891" last="4898">
<title>Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2.</title>
<authorList>
<person name="Mitsuuchi Y."/>
<person name="Johnson S.W."/>
<person name="Sonoda G."/>
<person name="Tanno S."/>
<person name="Golemis E.A."/>
<person name="Testa J.R."/>
</authorList>
<dbReference type="PubMed" id="10490823"/>
<dbReference type="DOI" id="10.1038/sj.onc.1203080"/>
</citation>
<scope>INTERACTION WITH APPL1</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2011" name="J. Cell Biol." volume="193" first="1275" last="1288">
<title>Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} regulates invadopodia formation.</title>
<authorList>
<person name="Yamaguchi H."/>
<person name="Yoshida S."/>
<person name="Muroi E."/>
<person name="Yoshida N."/>
<person name="Kawamura M."/>
<person name="Kouchi Z."/>
<person name="Nakamura Y."/>
<person name="Sakai R."/>
<person name="Fukami K."/>
</authorList>
<dbReference type="PubMed" id="21708979"/>
<dbReference type="DOI" id="10.1083/jcb.201009126"/>
</citation>
<scope>FUNCTION IN INVADOPODIA FORMATION</scope>
<scope>CHARACTERIZATION OF VARIANTS LYS-545 AND ARG-1047</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2013" name="Oncotarget" volume="4" first="729" last="738">
<title>FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.</title>
<authorList>
<person name="Cipriano R."/>
<person name="Miskimen K.L."/>
<person name="Bryson B.L."/>
<person name="Foy C.R."/>
<person name="Bartel C.A."/>
<person name="Jackson M.W."/>
</authorList>
<dbReference type="PubMed" id="23676467"/>
</citation>
<scope>INTERACTION WITH FAM83B</scope>
</reference>
<reference key="7">
<citation type="journal article" date="2008" name="Cell Cycle" volume="7" first="1151" last="1156">
<title>Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.</title>
<authorList>
<person name="Huang C.-H."/>
<person name="Mandelker D."/>
<person name="Gabelli S.B."/>
<person name="Amzel L.M."/>
</authorList>
<dbReference type="PubMed" id="18418043"/>
<dbReference type="DOI" id="10.4161/cc.7.9.5817"/>
</citation>
<scope>REVIEW ON CANCER</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2008" name="Oncogene" volume="27" first="5486" last="5496">
<title>Class I PI3K in oncogenic cellular transformation.</title>
<authorList>
<person name="Zhao L."/>
<person name="Vogt P.K."/>
</authorList>
<dbReference type="PubMed" id="18794883"/>
<dbReference type="DOI" id="10.1038/onc.2008.244"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
<scope>REVIEW ON CANCER</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2009" name="Curr. Opin. Cell Biol." volume="21" first="199" last="208">
<title>Should individual PI3 kinase isoforms be targeted in cancer?</title>
<authorList>
<person name="Jia S."/>
<person name="Roberts T.M."/>
<person name="Zhao J.J."/>
</authorList>
<dbReference type="PubMed" id="19200708"/>
<dbReference type="DOI" id="10.1016/j.ceb.2008.12.007"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2007" name="Science" volume="318" first="1744" last="1748">
<title>The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.</title>
<authorList>
<person name="Huang C.-H."/>
<person name="Mandelker D."/>
<person name="Schmidt-Kittler O."/>
<person name="Samuels Y."/>
<person name="Velculescu V.E."/>
<person name="Kinzler K.W."/>
<person name="Vogelstein B."/>
<person name="Gabelli S.B."/>
<person name="Amzel L.M."/>
</authorList>
<dbReference type="PubMed" id="18079394"/>
<dbReference type="DOI" id="10.1126/science.1150799"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1</scope>
<scope>DOMAINS</scope>
</reference>
<reference key="11">
<citation type="submission" date="2008-04" db="PDB data bank">
<title>Solution structure of the C2 domain from human PI3-kinase p110 subunit alpha.</title>
<authorList>
<consortium name="RIKEN structural genomics initiative (RSGI)"/>
</authorList>
</citation>
<scope>STRUCTURE BY NMR OF 331-481</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2009" name="Proc. Natl. Acad. Sci. U.S.A." volume="106" first="16996" last="17001">
<title>A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.</title>
<authorList>
<person name="Mandelker D."/>
<person name="Gabelli S.B."/>
<person name="Schmidt-Kittler O."/>
<person name="Zhu J."/>
<person name="Cheong I."/>
<person name="Huang C.H."/>
<person name="Kinzler K.W."/>
<person name="Vogelstein B."/>
<person name="Amzel L.M."/>
</authorList>
<dbReference type="PubMed" id="19805105"/>
<dbReference type="DOI" id="10.1073/pnas.0908444106"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX WITH WORTMANNIN AND PIK3R1</scope>
<scope>INTERACTION WITH PIK3R1</scope>
<scope>CHARACTERIZATION OF VARIANT ARG-1047</scope>
<scope>DOMAINS</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2004" name="Cancer Res." volume="64" first="5048" last="5050">
<title>Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.</title>
<authorList>
<person name="Broderick D.K."/>
<person name="Di C."/>
<person name="Parrett T.J."/>
<person name="Samuels Y.R."/>
<person name="Cummins J.M."/>
<person name="McLendon R.E."/>
<person name="Fults D.W."/>
<person name="Velculescu V.E."/>
<person name="Bigner D.D."/>
<person name="Yan H."/>
</authorList>
<dbReference type="PubMed" id="15289301"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-04-1170"/>
</citation>
<scope>VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047; LEU-1047 AND TYR-1065</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2004" name="Cancer Res." volume="64" first="7678" last="7681">
<title>Mutation of the PIK3CA gene in ovarian and breast cancer.</title>
<authorList>
<person name="Campbell I.G."/>
<person name="Russell S.E."/>
<person name="Choong D.Y.H."/>
<person name="Montgomery K.G."/>
<person name="Ciavarella M.L."/>
<person name="Hooi C.S.F."/>
<person name="Cristiano B.E."/>
<person name="Pearson R.B."/>
<person name="Phillips W.A."/>
</authorList>
<dbReference type="PubMed" id="15520168"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-04-2933"/>
</citation>
<scope>INVOLVEMENT IN OC</scope>
<scope>VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; ARG-1047 AND LEU-1047</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2004" name="Science" volume="304" first="554" last="554">
<title>High frequency of mutations of the PIK3CA gene in human cancers.</title>
<authorList>
<person name="Samuels Y."/>
<person name="Wang Z."/>
<person name="Bardelli A."/>
<person name="Silliman N."/>
<person name="Ptak J."/>
<person name="Szabo S."/>
<person name="Yan H."/>
<person name="Gazdar A."/>
<person name="Powell S.M."/>
<person name="Riggins G.J."/>
<person name="Willson J.K.V."/>
<person name="Markowitz S."/>
<person name="Kinzler K.W."/>
<person name="Vogelstein B."/>
<person name="Velculescu V.E."/>
</authorList>
<dbReference type="PubMed" id="15016963"/>
<dbReference type="DOI" id="10.1126/science.1096502"/>
</citation>
<scope>VARIANT CANCER ARG-1047</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2005" name="Acta Neuropathol." volume="109" first="639" last="642">
<title>PIK3CA mutations in glioblastoma multiforme.</title>
<authorList>
<person name="Hartmann C."/>
<person name="Bartels G."/>
<person name="Gehlhaar C."/>
<person name="Holtkamp N."/>
<person name="von Deimling A."/>
</authorList>
<dbReference type="PubMed" id="15924253"/>
<dbReference type="DOI" id="10.1007/s00401-005-1000-1"/>
</citation>
<scope>VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2005" name="BMC Cancer" volume="5" first="29" last="29">
<title>Mutations of PIK3CA in gastric adenocarcinoma.</title>
<authorList>
<person name="Li V.S.W."/>
<person name="Wong C.W."/>
<person name="Chan T.L."/>
<person name="Chan A.S.W."/>
<person name="Zhao W."/>
<person name="Chu K.-M."/>
<person name="So S."/>
<person name="Chen X."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
</authorList>
<dbReference type="PubMed" id="15784156"/>
<dbReference type="DOI" id="10.1186/1471-2407-5-29"/>
</citation>
<scope>VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2005" name="Cancer Res." volume="65" first="4562" last="4567">
<title>Functional analysis of PIK3CA gene mutations in human colorectal cancer.</title>
<authorList>
<person name="Ikenoue T."/>
<person name="Kanai F."/>
<person name="Hikiba Y."/>
<person name="Obata T."/>
<person name="Tanaka Y."/>
<person name="Imamura J."/>
<person name="Ohta M."/>
<person name="Jazag A."/>
<person name="Guleng B."/>
<person name="Tateishi K."/>
<person name="Asaoka Y."/>
<person name="Matsumura M."/>
<person name="Kawabe T."/>
<person name="Omata M."/>
</authorList>
<dbReference type="PubMed" id="15930273"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-04-4114"/>
</citation>
<scope>INVOLVEMENT IN CRC</scope>
<scope>CHARACTERIZATION OF VARIANTS CRC HIS-38; VAL-106; ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2005" name="Cancer Res." volume="65" first="10669" last="10673">
<title>High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.</title>
<authorList>
<person name="Oda K."/>
<person name="Stokoe D."/>
<person name="Taketani Y."/>
<person name="McCormick F."/>
</authorList>
<dbReference type="PubMed" id="16322209"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-05-2620"/>
</citation>
<scope>VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007; HIS-1021; CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050; LYS-1052 AND LEU-1065</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2005" name="Eur. J. Cancer" volume="41" first="1649" last="1654">
<title>The prevalence of PIK3CA mutations in gastric and colon cancer.</title>
<authorList>
<person name="Velho S."/>
<person name="Oliveira C."/>
<person name="Ferreira A."/>
<person name="Ferreira A.C."/>
<person name="Suriano G."/>
<person name="Schwartz S. Jr."/>
<person name="Duval A."/>
<person name="Carneiro F."/>
<person name="Machado J.C."/>
<person name="Hamelin R."/>
<person name="Seruca R."/>
</authorList>
<dbReference type="PubMed" id="15994075"/>
<dbReference type="DOI" id="10.1016/j.ejca.2005.04.022"/>
</citation>
<scope>INVOLVEMENT IN CRC</scope>
<scope>VARIANTS CANCER LYS-542; GLY-545; LYS-545; GLN-1023; ARG-1047 AND LEU-1047</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2005" name="Hum. Mutat." volume="25" first="322" last="322">
<title>PIK3CA mutations in advanced ovarian carcinomas.</title>
<authorList>
<person name="Wang Y."/>
<person name="Helland A."/>
<person name="Holm R."/>
<person name="Kristensen G.B."/>
<person name="Boerresen-Dale A.-L."/>
</authorList>
<dbReference type="PubMed" id="15712344"/>
<dbReference type="DOI" id="10.1002/humu.9316"/>
</citation>
<scope>VARIANTS CANCER LYS-545 AND ARG-1047</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2005" name="Oncogene" volume="24" first="1477" last="1480">
<title>PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.</title>
<authorList>
<person name="Lee J.W."/>
<person name="Soung Y.H."/>
<person name="Kim S.Y."/>
<person name="Lee H.W."/>
<person name="Park W.S."/>
<person name="Nam S.W."/>
<person name="Kim S.H."/>
<person name="Lee J.Y."/>
<person name="Yoo N.J."/>
<person name="Lee S.H."/>
</authorList>
<dbReference type="PubMed" id="15608678"/>
<dbReference type="DOI" id="10.1038/sj.onc.1208304"/>
</citation>
<scope>VARIANT HCC ALA-545</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2006" name="Clin. Cancer Res." volume="12" first="1441" last="1446">
<title>PIK3CA mutations in head and neck squamous cell carcinoma.</title>
<authorList>
<person name="Qiu W."/>
<person name="Schoenleben F."/>
<person name="Li X."/>
<person name="Ho D.J."/>
<person name="Close L.G."/>
<person name="Manolidis S."/>
<person name="Bennett B.P."/>
<person name="Su G.H."/>
</authorList>
<dbReference type="PubMed" id="16533766"/>
<dbReference type="DOI" id="10.1158/1078-0432.CCR-05-2173"/>
</citation>
<scope>VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047</scope>
<scope>VARIANT MET-391</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2006" name="Int. J. Cancer" volume="118" first="1065" last="1067">
<title>PIK3CA mutations in nasopharyngeal carcinoma.</title>
<authorList>
<person name="Or Y.Y.-Y."/>
<person name="Hui A.B.-Y."/>
<person name="To K.-F."/>
<person name="Lam C.N.-Y."/>
<person name="Lo K.-W."/>
</authorList>
<dbReference type="PubMed" id="16114017"/>
<dbReference type="DOI" id="10.1002/ijc.21444"/>
</citation>
<scope>VARIANT CANCER ARG-1047</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2006" name="J. Pathol." volume="208" first="350" last="355">
<title>PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.</title>
<authorList>
<person name="Buttitta F."/>
<person name="Felicioni L."/>
<person name="Barassi F."/>
<person name="Martella C."/>
<person name="Paolizzi D."/>
<person name="Fresu G."/>
<person name="Salvatore S."/>
<person name="Cuccurullo F."/>
<person name="Mezzetti A."/>
<person name="Campani D."/>
<person name="Marchetti A."/>
</authorList>
<dbReference type="PubMed" id="16353168"/>
<dbReference type="DOI" id="10.1002/path.1908"/>
</citation>
<scope>VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2006" name="Proc. Natl. Acad. Sci. U.S.A." volume="103" first="1475" last="1479">
<title>Cancer-specific mutations in PIK3CA are oncogenic in vivo.</title>
<authorList>
<person name="Bader A.G."/>
<person name="Kang S."/>
<person name="Vogt P.K."/>
</authorList>
<dbReference type="PubMed" id="16432179"/>
<dbReference type="DOI" id="10.1073/pnas.0510857103"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2007" name="Proc. Natl. Acad. Sci. U.S.A." volume="104" first="13450" last="13454">
<title>Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.</title>
<authorList>
<person name="Hafner C."/>
<person name="Lopez-Knowles E."/>
<person name="Luis N.M."/>
<person name="Toll A."/>
<person name="Baselga E."/>
<person name="Fernandez-Casado A."/>
<person name="Hernandez S."/>
<person name="Ribe A."/>
<person name="Mentzel T."/>
<person name="Stoehr R."/>
<person name="Hofstaedter F."/>
<person name="Landthaler M."/>
<person name="Vogt T."/>
<person name="Pujol R.M."/>
<person name="Hartmann A."/>
<person name="Real F.X."/>
</authorList>
<dbReference type="PubMed" id="17673550"/>
<dbReference type="DOI" id="10.1073/pnas.0705218104"/>
</citation>
<scope>VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2012" name="Am. J. Hum. Genet." volume="90" first="1108" last="1115">
<title>Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.</title>
<authorList>
<person name="Kurek K.C."/>
<person name="Luks V.L."/>
<person name="Ayturk U.M."/>
<person name="Alomari A.I."/>
<person name="Fishman S.J."/>
<person name="Spencer S.A."/>
<person name="Mulliken J.B."/>
<person name="Bowen M.E."/>
<person name="Yamamoto G.L."/>
<person name="Kozakewich H.P."/>
<person name="Warman M.L."/>
</authorList>
<dbReference type="PubMed" id="22658544"/>
<dbReference type="DOI" id="10.1016/j.ajhg.2012.05.006"/>
</citation>
<scope>VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2012" name="Nat. Genet." volume="44" first="934" last="940">
<title>De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes.</title>
<authorList>
<person name="Riviere J.B."/>
<person name="Mirzaa G.M."/>
<person name="O'Roak B.J."/>
<person name="Beddaoui M."/>
<person name="Alcantara D."/>
<person name="Conway R.L."/>
<person name="St-Onge J."/>
<person name="Schwartzentruber J.A."/>
<person name="Gripp K.W."/>
<person name="Nikkel S.M."/>
<person name="Worthylake T."/>
<person name="Sullivan C.T."/>
<person name="Ward T.R."/>
<person name="Butler H.E."/>
<person name="Kramer N.A."/>
<person name="Albrecht B."/>
<person name="Armour C.M."/>
<person name="Armstrong L."/>
<person name="Caluseriu O."/>
<person name="Cytrynbaum C."/>
<person name="Drolet B.A."/>
<person name="Innes A.M."/>
<person name="Lauzon J.L."/>
<person name="Lin A.E."/>
<person name="Mancini G.M."/>
<person name="Meschino W.S."/>
<person name="Reggin J.D."/>
<person name="Saggar A.K."/>
<person name="Lerman-Sagie T."/>
<person name="Uyanik G."/>
<person name="Weksberg R."/>
<person name="Zirn B."/>
<person name="Beaulieu C.L."/>
<person name="Majewski J."/>
<person name="Bulman D.E."/>
<person name="O'Driscoll M."/>
<person name="Shendure J."/>
<person name="Graham J.M. Jr."/>
<person name="Boycott K.M."/>
<person name="Dobyns W.B."/>
</authorList>
<dbReference type="PubMed" id="22729224"/>
<dbReference type="DOI" id="10.1038/ng.2331"/>
</citation>
<scope>VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL; LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043; TYR-1047 AND SER-1049</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2013" name="Am. J. Hum. Genet." volume="92" first="76" last="80">
<title>Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.</title>
<authorList>
<person name="Orloff M.S."/>
<person name="He X."/>
<person name="Peterson C."/>
<person name="Chen F."/>
<person name="Chen J.L."/>
<person name="Mester J.L."/>
<person name="Eng C."/>
</authorList>
<dbReference type="PubMed" id="23246288"/>
<dbReference type="DOI" id="10.1016/j.ajhg.2012.10.021"/>
</citation>
<scope>VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2016" name="Hum. Mutat." volume="37" first="242" last="245">
<title>Identification and characterisation of a novel constitutional PIK3CA mutation in a child lacking the typical segmental overgrowth of 'PIK3CA-related overgrowth spectrum' (PROS).</title>
<authorList>
<person name="Donato N.D."/>
<person name="Rump A."/>
<person name="Mirzaa G.M."/>
<person name="Alcantara D."/>
<person name="Oliver A."/>
<person name="Schrock E."/>
<person name="Dobyns W.B."/>
<person name="O'Driscoll M."/>
</authorList>
<dbReference type="PubMed" id="26593112"/>
<dbReference type="DOI" id="10.1002/humu.22933"/>
</citation>
<scope>VARIANT MCAP ASN-112</scope>
<scope>CHARACTERIZATION OF VARIANT MCAP ASN-112</scope>
<scope>FUNCTION</scope>
<scope>SUBUNIT</scope>
</reference>
<comment type="function">
<text evidence="21 44 49">Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Also has serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS. Plays a role in the positive regulation of phagocytosis and pinocytosis (By similarity).</text>
</comment>
<comment type="catalytic activity">
<text evidence="20">ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.</text>
</comment>
<comment type="catalytic activity">
<text evidence="20">ATP + a protein = ADP + a phosphoprotein.</text>
</comment>
<comment type="subunit">
<text evidence="21 48 49">Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory subunit (PIK3R1, PIK3R2 or PIK3R3) (PubMed:26593112). Interacts with IRS1 in nuclear extracts (By similarity). Interacts with RUFY3 (By similarity). Interacts with RASD2 (By similarity). Interacts with APPL1. Interacts with HRAS and KRAS (By similarity). Interaction with HRAS/KRAS is required for PI3K pathway signaling and cell proliferation stimulated by EGF and FGF2 (By similarity). Interacts with FAM83B; activates the PI3K/AKT signaling cascade (PubMed:23676467).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2116585"/>
<interactant intactId="EBI-720706">
<id>P21860</id>
<label>ERBB3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2116585"/>
<interactant intactId="EBI-517592">
<id>P35568</id>
<label>IRS1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>20</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2116585"/>
<interactant intactId="EBI-79464">
<id>P27986</id>
<label>PIK3R1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>14</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2116585"/>
<interactant intactId="EBI-79893">
<id>Q92569</id>
<label>PIK3R3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="domain">
<text evidence="42 43">The PI3K-ABD domain and the PI3K-RBD domain interact with the PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the recruitment to the plasma membrane. The inhibitory interactions with PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with the nSH2 (N-terminal SH2) region of PIK3R1.</text>
</comment>
<comment type="disease">
<text evidence="27 28 29 31 32 33 34 35 36 37 38 39 40 41 43 44 45 46">PIK3CA mutations are involved in various type of cancer. Most of the cancer-associated mutations are missense mutations and map to one of the three hotspots: Glu-542; Glu-545 and His-1047. Mutated isoforms participate in cellular transformation and tumorigenesis induced by oncogenic receptor tyrosine kinases (RTKs) and HRAS/KRAS. Interaction with HRAS/KRAS is required for Ras-driven tumor formation. Mutations increasing the lipid kinase activity are required for oncogenic signaling. The protein kinase activity may not be required for tumorigenesis.</text>
</comment>
<comment type="disease" evidence="34 35">
<disease id="DI-01359">
<name>Colorectal cancer</name>
<acronym>CRC</acronym>
<description>A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.</description>
<dbReference type="MIM" id="114500"/>
</disease>
<text>The gene represented in this entry may be involved in disease pathogenesis.</text>
</comment>
<comment type="disease" evidence="38">
<disease id="DI-02602">
<name>Breast cancer</name>
<acronym>BC</acronym>
<description>A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.</description>
<dbReference type="MIM" id="114480"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="29">
<disease id="DI-01655">
<name>Ovarian cancer</name>
<acronym>OC</acronym>
<description>The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.</description>
<dbReference type="MIM" id="167000"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="30">
<disease id="DI-01708">
<name>Hepatocellular carcinoma</name>
<acronym>HCC</acronym>
<description>A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.</description>
<dbReference type="MIM" id="114550"/>
</disease>
<text>The gene represented in this entry may be involved in disease pathogenesis.</text>
</comment>
<comment type="disease" evidence="41">
<disease id="DI-00625">
<name>Keratosis, seborrheic</name>
<acronym>KERSEB</acronym>
<description>A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.</description>
<dbReference type="MIM" id="182000"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="46 49">
<disease id="DI-03624">
<name>Megalencephaly-capillary malformation-polymicrogyria syndrome</name>
<acronym>MCAP</acronym>
<description>A syndrome characterized by a spectrum of anomalies including primary megalencephaly, prenatal overgrowth, brain and body asymmetry, cutaneous vascular malformations, digital anomalies consisting of syndactyly with or without postaxial polydactyly, connective tissue dysplasia involving the skin, subcutaneous tissue, and joints, and cortical brain malformations, most distinctively polymicrogyria.</description>
<dbReference type="MIM" id="602501"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="45">
<disease id="DI-03487">
<name>Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi</name>
<acronym>CLOVE</acronym>
<description>A sporadically occurring, non-hereditary disorder characterized by asymmetric somatic hypertrophy and anomalies in multiple organs. It is defined by four main clinical findings: congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal/spinal abnormalities. The presence of truncal overgrowth and characteristic patterned macrodactyly at birth differentiates CLOVE from other syndromic forms of overgrowth.</description>
<dbReference type="MIM" id="612918"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="47">
<disease id="DI-03696">
<name>Cowden syndrome 5</name>
<acronym>CWS5</acronym>
<description>A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid.</description>
<dbReference type="MIM" id="615108"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="miscellaneous">
<text evidence="52">The avian sarcoma virus 16 genome encodes an oncogene derived from PIK3CA.</text>
</comment>
<comment type="similarity">
<text evidence="23 25 26">Belongs to the PI3/PI4-kinase family.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/PIK3CAID415ch3q26.html"/>
</comment>
<dbReference type="EC" id="2.7.1.153" evidence="20"/>
<dbReference type="EC" id="2.7.11.1" evidence="20"/>
<dbReference type="EMBL" id="Z29090">
<property type="protein sequence ID" value="CAA82333.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="U79143">
<property type="protein sequence ID" value="AAB39753.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC113601">
<property type="protein sequence ID" value="AAI13602.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC113603">
<property type="protein sequence ID" value="AAI13604.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS43171.1"/>
<dbReference type="PIR" id="I38110">
<property type="entry name" value="I38110"/>
</dbReference>
<dbReference type="RefSeq" id="NP_006209.2">
<property type="nucleotide sequence ID" value="NM_006218.3"/>
</dbReference>
<dbReference type="RefSeq" id="XP_006713721.1">
<property type="nucleotide sequence ID" value="XM_006713658.3"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011511196.1">
<property type="nucleotide sequence ID" value="XM_011512894.2"/>
</dbReference>
<dbReference type="UniGene" id="Hs.553498"/>
<dbReference type="UniGene" id="Hs.715194"/>
<dbReference type="UniGene" id="Hs.732394"/>
<dbReference type="PDB" id="2ENQ">
<property type="method" value="NMR"/>
<property type="chains" value="A=331-481"/>
</dbReference>
<dbReference type="PDB" id="2RD0">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.05"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="3HHM">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="3HIZ">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.30"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="3ZIM">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.85"/>
<property type="chains" value="A=107-1046"/>
</dbReference>
<dbReference type="PDB" id="4JPS">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="4L1B">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.59"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="4L23">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="4L2Y">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="4OVU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.96"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="4OVV">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.50"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="4TUU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.64"/>
<property type="chains" value="A=105-1048"/>
</dbReference>
<dbReference type="PDB" id="4TV3">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.85"/>
<property type="chains" value="A=105-1048"/>
</dbReference>
<dbReference type="PDB" id="4WAF">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.39"/>
<property type="chains" value="A=2-1068"/>
</dbReference>
<dbReference type="PDB" id="4YKN">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="A=2-1068"/>
</dbReference>
<dbReference type="PDB" id="4ZOP">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.62"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5DXH">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="A/D=2-1068"/>
</dbReference>
<dbReference type="PDB" id="5DXT">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.25"/>
<property type="chains" value="A=107-1068"/>
</dbReference>
<dbReference type="PDB" id="5FI4">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5ITD">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.02"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SW8">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.30"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SWG">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.11"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SWO">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.50"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SWP">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.41"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SWR">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.31"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SWT">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.49"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SX8">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.47"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SX9">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.52"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXA">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.35"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXB">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.30"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXC">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.55"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXD">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.50"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXE">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.51"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXF">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.46"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXI">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.40"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.42"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5SXK">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.55"/>
<property type="chains" value="A=1-1068"/>
</dbReference>
<dbReference type="PDB" id="5UBR">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A=107-1050"/>
</dbReference>
<dbReference type="PDBsum" id="2ENQ"/>
<dbReference type="PDBsum" id="2RD0"/>
<dbReference type="PDBsum" id="3HHM"/>
<dbReference type="PDBsum" id="3HIZ"/>
<dbReference type="PDBsum" id="3ZIM"/>
<dbReference type="PDBsum" id="4JPS"/>
<dbReference type="PDBsum" id="4L1B"/>
<dbReference type="PDBsum" id="4L23"/>
<dbReference type="PDBsum" id="4L2Y"/>
<dbReference type="PDBsum" id="4OVU"/>
<dbReference type="PDBsum" id="4OVV"/>
<dbReference type="PDBsum" id="4TUU"/>
<dbReference type="PDBsum" id="4TV3"/>
<dbReference type="PDBsum" id="4WAF"/>
<dbReference type="PDBsum" id="4YKN"/>
<dbReference type="PDBsum" id="4ZOP"/>
<dbReference type="PDBsum" id="5DXH"/>
<dbReference type="PDBsum" id="5DXT"/>
<dbReference type="PDBsum" id="5FI4"/>
<dbReference type="PDBsum" id="5ITD"/>
<dbReference type="PDBsum" id="5SW8"/>
<dbReference type="PDBsum" id="5SWG"/>
<dbReference type="PDBsum" id="5SWO"/>
<dbReference type="PDBsum" id="5SWP"/>
<dbReference type="PDBsum" id="5SWR"/>
<dbReference type="PDBsum" id="5SWT"/>
<dbReference type="PDBsum" id="5SX8"/>
<dbReference type="PDBsum" id="5SX9"/>
<dbReference type="PDBsum" id="5SXA"/>
<dbReference type="PDBsum" id="5SXB"/>
<dbReference type="PDBsum" id="5SXC"/>
<dbReference type="PDBsum" id="5SXD"/>
<dbReference type="PDBsum" id="5SXE"/>
<dbReference type="PDBsum" id="5SXF"/>
<dbReference type="PDBsum" id="5SXI"/>
<dbReference type="PDBsum" id="5SXJ"/>
<dbReference type="PDBsum" id="5SXK"/>
<dbReference type="PDBsum" id="5UBR"/>
<dbReference type="ProteinModelPortal" id="P42336"/>
<dbReference type="SMR" id="P42336"/>
<dbReference type="BioGrid" id="111308">
<property type="interactions" value="77"/>
</dbReference>
<dbReference type="DIP" id="DIP-42728N"/>
<dbReference type="IntAct" id="P42336">
<property type="interactions" value="46"/>
</dbReference>
<dbReference type="MINT" id="MINT-1367228"/>
<dbReference type="STRING" id="9606.ENSP00000263967"/>
<dbReference type="BindingDB" id="P42336"/>
<dbReference type="ChEMBL" id="CHEMBL4005"/>
<dbReference type="DrugBank" id="DB00201">
<property type="generic name" value="Caffeine"/>
</dbReference>
<dbReference type="DrugBank" id="DB05240">
<property type="generic name" value="XL147"/>
</dbReference>
<dbReference type="DrugBank" id="DB05241">
<property type="generic name" value="XL765"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="2153"/>
<dbReference type="iPTMnet" id="P42336"/>
<dbReference type="PhosphoSitePlus" id="P42336"/>
<dbReference type="BioMuta" id="PI3KCA"/>
<dbReference type="DMDM" id="126302584"/>
<dbReference type="EPD" id="P42336"/>
<dbReference type="MaxQB" id="P42336"/>
<dbReference type="PaxDb" id="P42336"/>
<dbReference type="PeptideAtlas" id="P42336"/>
<dbReference type="PRIDE" id="P42336"/>
<dbReference type="DNASU" id="5290"/>
<dbReference type="Ensembl" id="ENST00000263967">
<property type="protein sequence ID" value="ENSP00000263967"/>
<property type="gene ID" value="ENSG00000121879"/>
</dbReference>
<dbReference type="GeneID" id="5290"/>
<dbReference type="KEGG" id="hsa:5290"/>
<dbReference type="UCSC" id="uc003fjk.4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="5290"/>
<dbReference type="DisGeNET" id="5290"/>
<dbReference type="GeneCards" id="PIK3CA"/>
<dbReference type="GeneReviews" id="PIK3CA"/>
<dbReference type="HGNC" id="HGNC:8975">
<property type="gene designation" value="PIK3CA"/>
</dbReference>
<dbReference type="HPA" id="CAB017804"/>
<dbReference type="HPA" id="HPA009985"/>
<dbReference type="MalaCards" id="PIK3CA"/>
<dbReference type="MIM" id="114480">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="114500">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="114550">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="167000">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="171834">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="182000">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="602501">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="612918">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="615108">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P42336"/>
<dbReference type="OpenTargets" id="ENSG00000121879"/>
<dbReference type="Orphanet" id="140944">
<property type="disease" value="CLOVE syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="201">
<property type="disease" value="Cowden syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="276280">
<property type="disease" value="Hemihyperplasia-multiple lipomatosis syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="99802">
<property type="disease" value="Hemimegalencephaly"/>
</dbReference>
<dbReference type="Orphanet" id="144">
<property type="disease" value="Hereditary nonpolyposis colon cancer"/>
</dbReference>
<dbReference type="Orphanet" id="295239">
<property type="disease" value="Macrodactyly of fingers, unilateral"/>
</dbReference>
<dbReference type="Orphanet" id="295243">
<property type="disease" value="Macrodactyly of toes, unilateral"/>
</dbReference>
<dbReference type="Orphanet" id="60040">
<property type="disease" value="Megalencephaly-capillary malformation-polymicrogyria syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="314662">
<property type="disease" value="Segmental progressive overgrowth syndrome with fibroadipose hyperplasia"/>
</dbReference>
<dbReference type="PharmGKB" id="PA33308"/>
<dbReference type="eggNOG" id="KOG0904">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG5032">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000119110"/>
<dbReference type="HOVERGEN" id="HBG052721"/>
<dbReference type="InParanoid" id="P42336"/>
<dbReference type="KO" id="K00922"/>
<dbReference type="OMA" id="PMVRAFA"/>
<dbReference type="OrthoDB" id="EOG091G027R"/>
<dbReference type="PhylomeDB" id="P42336"/>
<dbReference type="TreeFam" id="TF102031"/>
<dbReference type="BioCyc" id="MetaCyc:HS04527-MONOMER"/>
<dbReference type="BRENDA" id="2.7.1.137">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="BRENDA" id="2.7.1.153">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-109704">
<property type="pathway name" value="PI3K Cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-114604">
<property type="pathway name" value="GPVI-mediated activation cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1236382">
<property type="pathway name" value="Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1250342">
<property type="pathway name" value="PI3K events in ERBB4 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1257604">
<property type="pathway name" value="PIP3 activates AKT signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1433557">
<property type="pathway name" value="Signaling by SCF-KIT"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1660499">
<property type="pathway name" value="Synthesis of PIPs at the plasma membrane"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-180292">
<property type="pathway name" value="GAB1 signalosome"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1839117">
<property type="pathway name" value="Signaling by cytosolic FGFR1 fusion mutants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-186763">
<property type="pathway name" value="Downstream signal transduction"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1963642">
<property type="pathway name" value="PI3K events in ERBB2 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-198203">
<property type="pathway name" value="PI3K/AKT activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-202424">
<property type="pathway name" value="Downstream TCR signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2029485">
<property type="pathway name" value="Role of phospholipids in phagocytosis"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-210993">
<property type="pathway name" value="Tie2 Signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2219530">
<property type="pathway name" value="Constitutive Signaling by Aberrant PI3K in Cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2424491">
<property type="pathway name" value="DAP12 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2730905">
<property type="pathway name" value="Role of LAT2/NTAL/LAB on calcium mobilization"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-373753">
<property type="pathway name" value="Nephrin interactions"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-388841">
<property type="pathway name" value="Costimulation by the CD28 family"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-389357">
<property type="pathway name" value="CD28 dependent PI3K/Akt signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-392451">
<property type="pathway name" value="G beta:gamma signalling through PI3Kgamma"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-416476">
<property type="pathway name" value="G alpha (q) signalling events"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-416482">
<property type="pathway name" value="G alpha (12/13) signalling events"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-4420097">
<property type="pathway name" value="VEGFA-VEGFR2 Pathway"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-512988">
<property type="pathway name" value="Interleukin-3, 5 and GM-CSF signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5637810">
<property type="pathway name" value="Constitutive Signaling by EGFRvIII"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654689">
<property type="pathway name" value="PI-3K cascade:FGFR1"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654695">
<property type="pathway name" value="PI-3K cascade:FGFR2"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654710">
<property type="pathway name" value="PI-3K cascade:FGFR3"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654720">
<property type="pathway name" value="PI-3K cascade:FGFR4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5655253">
<property type="pathway name" value="Signaling by FGFR2 in disease"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5655291">
<property type="pathway name" value="Signaling by FGFR4 in disease"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5655302">
<property type="pathway name" value="Signaling by FGFR1 in disease"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6811558">
<property type="pathway name" value="PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8851907">
<property type="pathway name" value="MET activates PI3K/AKT signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8853334">
<property type="pathway name" value="Signaling by FGFR3 fusions in cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8853338">
<property type="pathway name" value="Signaling by FGFR3 point mutants in cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8853659">
<property type="pathway name" value="RET signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-912526">
<property type="pathway name" value="Interleukin receptor SHC signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-912631">
<property type="pathway name" value="Regulation of signaling by CBL"/>
</dbReference>
<dbReference type="SignaLink" id="P42336"/>
<dbReference type="SIGNOR" id="P42336"/>
<dbReference type="ChiTaRS" id="PIK3CA">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P42336"/>
<dbReference type="GeneWiki" id="P110%CE%B1"/>
<dbReference type="GenomeRNAi" id="5290"/>
<dbReference type="PRO" id="PR:P42336"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 3"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000121879"/>
<dbReference type="CleanEx" id="HS_PIK3CA"/>
<dbReference type="ExpressionAtlas" id="P42336">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P42336">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0030027">
<property type="term" value="C:lamellipodium"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005942">
<property type="term" value="C:phosphatidylinositol 3-kinase complex"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005943">
<property type="term" value="C:phosphatidylinositol 3-kinase complex, class IA"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0016303">
<property type="term" value="F:1-phosphatidylinositol-3-kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035005">
<property type="term" value="F:1-phosphatidylinositol-4-phosphate 3-kinase activity"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0043560">
<property type="term" value="F:insulin receptor substrate binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016301">
<property type="term" value="F:kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0035004">
<property type="term" value="F:phosphatidylinositol 3-kinase activity"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046934">
<property type="term" value="F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0030295">
<property type="term" value="F:protein kinase activator activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0004674">
<property type="term" value="F:protein serine/threonine kinase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0060612">
<property type="term" value="P:adipose tissue development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001525">
<property type="term" value="P:angiogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0043276">
<property type="term" value="P:anoikis"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0007411">
<property type="term" value="P:axon guidance"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0060048">
<property type="term" value="P:cardiac muscle contraction"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071333">
<property type="term" value="P:cellular response to glucose stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043542">
<property type="term" value="P:endothelial cell migration"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0097009">
<property type="term" value="P:energy homeostasis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007173">
<property type="term" value="P:epidermal growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0038128">
<property type="term" value="P:ERBB2 signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0038095">
<property type="term" value="P:Fc-epsilon receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0038096">
<property type="term" value="P:Fc-gamma receptor signaling pathway involved in phagocytosis"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006006">
<property type="term" value="P:glucose metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0044029">
<property type="term" value="P:hypomethylation of CpG island"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0038028">
<property type="term" value="P:insulin receptor signaling pathway via phosphatidylinositol 3-kinase"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050900">
<property type="term" value="P:leukocyte migration"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0001889">
<property type="term" value="P:liver development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:2000811">
<property type="term" value="P:negative regulation of anoikis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000270">
<property type="term" value="P:negative regulation of fibroblast apoptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016242">
<property type="term" value="P:negative regulation of macroautophagy"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043524">
<property type="term" value="P:negative regulation of neuron apoptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006661">
<property type="term" value="P:phosphatidylinositol biosynthetic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0046854">
<property type="term" value="P:phosphatidylinositol phosphorylation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0048015">
<property type="term" value="P:phosphatidylinositol-mediated signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0016310">
<property type="term" value="P:phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0030168">
<property type="term" value="P:platelet activation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0033138">
<property type="term" value="P:positive regulation of peptidyl-serine phosphorylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032008">
<property type="term" value="P:positive regulation of TOR signaling"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043491">
<property type="term" value="P:protein kinase B signaling"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043457">
<property type="term" value="P:regulation of cellular respiration"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010468">
<property type="term" value="P:regulation of gene expression"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:2000653">
<property type="term" value="P:regulation of genetic imprinting"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0040014">
<property type="term" value="P:regulation of multicellular organism growth"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0014066">
<property type="term" value="P:regulation of phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0031295">
<property type="term" value="P:T cell costimulation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0050852">
<property type="term" value="P:T cell receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0048010">
<property type="term" value="P:vascular endothelial growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0001944">
<property type="term" value="P:vasculature development"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="Gene3D" id="1.10.1070.11">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.150">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR016024">
<property type="entry name" value="ARM-type_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR000008">
<property type="entry name" value="C2_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR000403">
<property type="entry name" value="PI3/4_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR018936">
<property type="entry name" value="PI3/4_kinase_CS"/>
</dbReference>
<dbReference type="InterPro" id="IPR003113">
<property type="entry name" value="PI3K_adapt-bd_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR002420">
<property type="entry name" value="PI3K_C2_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR000341">
<property type="entry name" value="PI3K_Ras-bd_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR015433">
<property type="entry name" value="PI_Kinase"/>
</dbReference>
<dbReference type="InterPro" id="IPR001263">
<property type="entry name" value="PInositide-3_kin_accessory_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR029071">
<property type="entry name" value="Ubiquitin-rel_dom"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR10048">
<property type="entry name" value="PTHR10048"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00454">
<property type="entry name" value="PI3_PI4_kinase"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00792">
<property type="entry name" value="PI3K_C2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF02192">
<property type="entry name" value="PI3K_p85B"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00794">
<property type="entry name" value="PI3K_rbd"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00613">
<property type="entry name" value="PI3Ka"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00142">
<property type="entry name" value="PI3K_C2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00143">
<property type="entry name" value="PI3K_p85B"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00144">
<property type="entry name" value="PI3K_rbd"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00145">
<property type="entry name" value="PI3Ka"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00146">
<property type="entry name" value="PI3Kc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48371">
<property type="entry name" value="SSF48371"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF49562">
<property type="entry name" value="SSF49562"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF54236">
<property type="entry name" value="SSF54236"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00915">
<property type="entry name" value="PI3_4_KINASE_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00916">
<property type="entry name" value="PI3_4_KINASE_2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50290">
<property type="entry name" value="PI3_4_KINASE_3"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51544">
<property type="entry name" value="PI3K_ABD"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51547">
<property type="entry name" value="PI3K_C2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51546">
<property type="entry name" value="PI3K_RBD"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51545">
<property type="entry name" value="PIK_HELICAL"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0037">Angiogenesis</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0581">Phagocytosis</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0656">Proto-oncogene</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0723">Serine/threonine-protein kinase</keyword>
<keyword id="KW-0808">Transferase</keyword>
<feature type="chain" description="Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform" id="PRO_0000088785">
<location>
<begin position="1"/>
<end position="1068"/>
</location>
</feature>
<feature type="domain" description="PI3K-ABD" evidence="23">
<location>
<begin position="16"/>
<end position="105"/>
</location>
</feature>
<feature type="domain" description="PI3K-RBD" evidence="25">
<location>
<begin position="187"/>
<end position="289"/>
</location>
</feature>
<feature type="domain" description="C2 PI3K-type" evidence="26">
<location>
<begin position="330"/>
<end position="487"/>
</location>
</feature>
<feature type="domain" description="PIK helical" evidence="24">
<location>
<begin position="517"/>
<end position="694"/>
</location>
</feature>
<feature type="domain" description="PI3K/PI4K" evidence="22">
<location>
<begin position="797"/>
<end position="1068"/>
</location>
</feature>
<feature type="sequence variant" description="In CRC; likely involved in disease pathogenesis; shows an increase in lipid kinase activity; may disrupt the interaction between the PI3K-ABD domain and the N-terminal lobe of PI3K/PI4K kinase domain possibly affecting the conformation of the kinase domain; dbSNP:rs772110575." id="VAR_026166" evidence="34">
<original>R</original>
<variation>H</variation>
<location>
<position position="38"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1051399." id="VAR_042942" evidence="50">
<original>I</original>
<variation>V</variation>
<location>
<position position="43"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP." id="VAR_069251" evidence="46">
<original>E</original>
<variation>K</variation>
<location>
<position position="81"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; also found in a glioblastoma multiforme sample; dbSNP:rs121913287." id="VAR_026167" evidence="33 46">
<original>R</original>
<variation>Q</variation>
<location>
<position position="88"/>
</location>
</feature>
<feature type="sequence variant" description="In CRC; likely involved in disease pathogenesis; shows an increase in lipid kinase activity." id="VAR_026168" evidence="34">
<original>G</original>
<variation>V</variation>
<location>
<position position="106"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; increased phosphatidylinositol 3-kinase signaling; decreased interaction with p85 regulatory subunit; no effect on protein abundance; dbSNP:rs863225460." id="VAR_075634" evidence="49">
<original>I</original>
<variation>N</variation>
<location>
<position position="112"/>
</location>
</feature>
<feature type="sequence variant" description="In CWS5; dbSNP:rs587777790." id="VAR_069786" evidence="47">
<original>G</original>
<variation>D</variation>
<location>
<position position="118"/>
</location>
</feature>
<feature type="sequence variant" description="In CWS5; dbSNP:rs587777791." id="VAR_069787" evidence="47">
<original>E</original>
<variation>K</variation>
<location>
<position position="135"/>
</location>
</feature>
<feature type="sequence variant" description="In CWS5; dbSNP:rs587777792." id="VAR_069788" evidence="47">
<original>E</original>
<variation>K</variation>
<location>
<position position="218"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1051407." id="VAR_042943" evidence="50">
<original>S</original>
<variation>R</variation>
<location>
<position position="332"/>
</location>
</feature>
<feature type="sequence variant" description="Found in a cancer sample; unknown pathological significance." id="VAR_026169" evidence="40">
<original>Y</original>
<variation>C</variation>
<location>
<position position="343"/>
</location>
</feature>
<feature type="sequence variant" description="In CWS5; dbSNP:rs587777793." id="VAR_069789" evidence="47">
<original>V</original>
<variation>I</variation>
<location>
<position position="356"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP." id="VAR_069252" evidence="46">
<original>G</original>
<variation>R</variation>
<location>
<position position="364"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP." id="VAR_069253" evidence="46">
<original>E</original>
<variation>K</variation>
<location>
<position position="365"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; dbSNP:rs397514565." id="VAR_069254" evidence="46">
<original>C</original>
<variation>Y</variation>
<location>
<position position="378"/>
</location>
</feature>
<feature type="sequence variant" description="In CWS5; dbSNP:rs587777794." id="VAR_069790" evidence="47">
<original>R</original>
<variation>K</variation>
<location>
<position position="382"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs2230461." id="VAR_026170" evidence="40">
<original>I</original>
<variation>M</variation>
<location>
<position position="391"/>
</location>
</feature>
<feature type="sequence variant" description="In CLOVE and CRC; shows an increase in lipid kinase activity; may increase the affinity for lipid membranes; dbSNP:rs121913272." id="VAR_026171" evidence="34 45">
<original>C</original>
<variation>R</variation>
<location>
<position position="420"/>
</location>
</feature>
<feature type="sequence variant" description="In CRC; likely involved in disease pathogenesis; shows an increase in lipid kinase activity; may disrupt the interaction of the C2 PI3K-type domain with the iSH2 region of the p85 regulatory subunit." id="VAR_026172" evidence="34">
<original>E</original>
<variation>Q</variation>
<location>
<position position="453"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP." id="VAR_069255" evidence="46">
<location>
<position position="453"/>
</location>
</feature>
<feature type="sequence variant" description="In CLOVE, KERSEB, CRC and BC; also found in glioblastoma multiforme and endometrial carcinoma; shows an increase in lipid kinase activity; oncogenic in vivo; occurs in the interface between the PI3K helical domain and the nSH2 (N-terminal SH2) region of the p85 regulatory subunit and may reduce the inhibitory effect of p85; requires interaction with RAS to induce cellular transformation; dbSNP:rs121913273." id="VAR_026173" evidence="28 32 33 34 35 37 38 39 40 41 45">
<original>E</original>
<variation>K</variation>
<location>
<position position="542"/>
</location>
</feature>
<feature type="sequence variant" description="Found in an endometrial carcinoma sample; unknown pathological significance." id="VAR_026174" evidence="37">
<original>E</original>
<variation>Q</variation>
<location>
<position position="542"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance." id="VAR_026175" evidence="38">
<original>E</original>
<variation>V</variation>
<location>
<position position="542"/>
</location>
</feature>
<feature type="sequence variant" description="In CWS5 and HCC; also found in a glioblastoma multiforme sample; dbSNP:rs121913274." id="VAR_026176" evidence="30 33 47">
<original>E</original>
<variation>A</variation>
<location>
<position position="545"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB; also found in an endometrial carcinoma sample; dbSNP:rs121913274." id="VAR_026177" evidence="29 35 37 41">
<original>E</original>
<variation>G</variation>
<location>
<position position="545"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP, KERSEB, CRC and BC; shows an increase in lipid kinase activity; oncogenic in vivo; occurs in the interface between the PI3K helical domain and the nSH2 (N-terminal SH2) region of the p85 regulatory subunit and may reduce the inhibitory effect of p85; requires interaction with RAS to induce cellular transformation; enhances invadopodia-mediated extracellular matrix degradation and invasion in breast cancer cells; dbSNP:rs104886003." id="VAR_026178" evidence="28 29 31 32 34 35 37 38 39 40 41 44 46">
<original>E</original>
<variation>K</variation>
<location>
<position position="545"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs121913286." id="VAR_026179" evidence="29">
<original>Q</original>
<variation>E</variation>
<location>
<position position="546"/>
</location>
</feature>
<feature type="sequence variant" description="In OC; unknown pathological significance; dbSNP:rs121913286." id="VAR_026180" evidence="29">
<original>Q</original>
<variation>K</variation>
<location>
<position position="546"/>
</location>
</feature>
<feature type="sequence variant" description="Found in an anaplastic astrocytoma sample; unknown pathological significance." id="VAR_026181" evidence="28">
<original>Q</original>
<variation>P</variation>
<location>
<position position="546"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs397517201." id="VAR_026182" evidence="38">
<original>Q</original>
<variation>R</variation>
<location>
<position position="546"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; dbSNP:rs867262025." id="VAR_069256" evidence="46">
<original>E</original>
<variation>K</variation>
<location>
<position position="726"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; dbSNP:rs587776932." id="VAR_069257" evidence="46">
<original>G</original>
<variation>R</variation>
<location>
<position position="914"/>
</location>
</feature>
<feature type="sequence variant" description="Found in an endometrial carcinoma sample; unknown pathological significance." id="VAR_026183" evidence="37">
<original>G</original>
<variation>R</variation>
<location>
<position position="1007"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; also found in an endometrial carcinoma sample; dbSNP:rs121913288." id="VAR_026184" evidence="37 46">
<original>Y</original>
<variation>C</variation>
<location>
<position position="1021"/>
</location>
</feature>
<feature type="sequence variant" description="Found in an endometrial carcinoma sample; unknown pathological significance." id="VAR_026185" evidence="37">
<original>Y</original>
<variation>H</variation>
<location>
<position position="1021"/>
</location>
</feature>
<feature type="sequence variant" description="Found in a glioblastoma multiforme sample; unknown pathological significance." id="VAR_026186" evidence="28">
<original>Y</original>
<variation>N</variation>
<location>
<position position="1021"/>
</location>
</feature>
<feature type="sequence variant" description="In CRC; unknown pathological significance." id="VAR_026187" evidence="35">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1023"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; dbSNP:rs397517202." id="VAR_069258" evidence="46">
<original>T</original>
<variation>A</variation>
<location>
<position position="1025"/>
</location>
</feature>
<feature type="sequence variant" description="Found in a glioblastoma multiforme sample; unknown pathological significance." id="VAR_026188" evidence="33">
<original>T</original>
<variation>N</variation>
<location>
<position position="1025"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; also found in an endometrial carcinoma sample." id="VAR_026189" evidence="37 46">
<original>A</original>
<variation>V</variation>
<location>
<position position="1035"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP and CRC; also found in an endometrial carcinoma sample; shows an increase in lipid kinase activity; dbSNP:rs121913283." id="VAR_026190" evidence="34 37 46">
<original>M</original>
<variation>I</variation>
<location>
<position position="1043"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs121913279." id="VAR_026191" evidence="28 29 35 38">
<original>H</original>
<variation>L</variation>
<location>
<position position="1047"/>
</location>
</feature>
<feature type="sequence variant" description="In CLOVE, KERSEB, CRC, BC and OC; also found in an endometrial carcinoma sample; shows an increase in lipid kinase activity; oncogenic in vivo; requires binding to p85 regulatory subunit to induce cellular transformation but not interaction with RAS; may mimic the conformatitonal change triggered by the interaction with RAS; enhances invadopodia-mediated extracellular matrix degradation and invasion in breast cancer cells; increases lipid kinase activity; may alter the interaction of the PI3K/PI4K kinase domain with the cell membrane; dbSNP:rs121913279." id="VAR_026192" evidence="27 28 29 31 32 34 35 36 37 38 39 40 41 43 44 45">
<original>H</original>
<variation>R</variation>
<location>
<position position="1047"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; also found in an endometrial carcinoma sample; dbSNP:rs121913281." id="VAR_026193" evidence="37 46">
<original>H</original>
<variation>Y</variation>
<location>
<position position="1047"/>
</location>
</feature>
<feature type="sequence variant" description="In MCAP; dbSNP:rs121913277." id="VAR_069259" evidence="46">
<original>G</original>
<variation>S</variation>
<location>
<position position="1049"/>
</location>
</feature>
<feature type="sequence variant" description="Found in an endometrial carcinoma sample; unknown pathological significance." id="VAR_026194" evidence="37">
<original>G</original>
<variation>D</variation>
<location>
<position position="1050"/>
</location>
</feature>
<feature type="sequence variant" description="Found in an endometrial carcinoma sample; unknown pathological significance." id="VAR_026195" evidence="37">
<original>T</original>
<variation>K</variation>
<location>
<position position="1052"/>
</location>
</feature>
<feature type="sequence variant" description="Found in an endometrial carcinoma sample; unknown pathological significance." id="VAR_026196" evidence="37">
<original>H</original>
<variation>L</variation>
<location>
<position position="1065"/>
</location>
</feature>
<feature type="sequence variant" description="Found in brain tumors; unknown pathological significance." id="VAR_026197" evidence="28">
<original>H</original>
<variation>Y</variation>
<location>
<position position="1065"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA82333." ref="1" evidence="51">
<original>N</original>
<variation>H</variation>
<location>
<position position="170"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA82333." ref="1" evidence="51">
<original>K</original>
<variation>R</variation>
<location>
<position position="187"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA82333." ref="1" evidence="51">
<original>ML</original>
<variation>KM</variation>
<location>
<begin position="286"/>
<end position="287"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA82333." ref="1" evidence="51">
<original>V</original>
<variation>L</variation>
<location>
<position position="346"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA82333." ref="1" evidence="51">
<original>K</original>
<variation>R</variation>
<location>
<position position="723"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA82333." ref="1" evidence="51">
<original>F</original>
<variation>L</variation>
<location>
<position position="751"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA82333." ref="1" evidence="51">
<original>E</original>
<variation>K</variation>
<location>
<position position="767"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="5"/>
<end position="10"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="13"/>
<end position="15"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="18"/>
<end position="25"/>
</location>
</feature>
<feature type="strand" evidence="15">
<location>
<begin position="27"/>
<end position="29"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="31"/>
<end position="37"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="42"/>
<end position="52"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="53"/>
<end position="55"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="56"/>
<end position="58"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="59"/>
<end position="61"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="65"/>
<end position="67"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="69"/>
<end position="74"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="75"/>
<end position="77"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="79"/>
<end position="82"/>
</location>
</feature>
<feature type="strand" evidence="15">
<location>
<begin position="86"/>
<end position="88"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="89"/>
<end position="91"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="94"/>
<end position="102"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="105"/>
<end position="107"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="108"/>
<end position="121"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="126"/>
<end position="130"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="134"/>
<end position="142"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="144"/>
<end position="155"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="156"/>
<end position="159"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="160"/>
<end position="166"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="179"/>
<end position="182"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="185"/>
<end position="198"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="199"/>
<end position="202"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="203"/>
<end position="212"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="217"/>
<end position="226"/>
</location>
</feature>
<feature type="turn" evidence="14">
<location>
<begin position="228"/>
<end position="230"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="232"/>
<end position="234"/>
</location>
</feature>
<feature type="helix" evidence="10">
<location>
<begin position="237"/>
<end position="242"/>
</location>
</feature>
<feature type="turn" evidence="6">
<location>
<begin position="243"/>
<end position="245"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="246"/>
<end position="248"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="249"/>
<end position="254"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="255"/>
<end position="258"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="263"/>
<end position="265"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="267"/>
<end position="269"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="271"/>
<end position="279"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="284"/>
<end position="289"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="290"/>
<end position="294"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="306"/>
<end position="309"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="319"/>
<end position="321"/>
</location>
</feature>
<feature type="strand" evidence="13">
<location>
<begin position="323"/>
<end position="326"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="327"/>
<end position="329"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="332"/>
<end position="342"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="348"/>
<end position="350"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="353"/>
<end position="362"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="365"/>
<end position="368"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="376"/>
<end position="379"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="382"/>
<end position="392"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="393"/>
<end position="395"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="401"/>
<end position="413"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="416"/>
<end position="430"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="434"/>
<end position="436"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="439"/>
<end position="444"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="454"/>
<end position="456"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="458"/>
<end position="460"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="468"/>
<end position="470"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="472"/>
<end position="477"/>
</location>
</feature>
<feature type="strand" evidence="13">
<location>
<begin position="481"/>
<end position="485"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="489"/>
<end position="492"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="495"/>
<end position="498"/>
</location>
</feature>
<feature type="strand" evidence="17">
<location>
<begin position="504"/>
<end position="506"/>
</location>
</feature>
<feature type="helix" evidence="13">
<location>
<begin position="508"/>
<end position="512"/>
</location>
</feature>
<feature type="helix" evidence="19">
<location>
<begin position="513"/>
<end position="515"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="517"/>
<end position="520"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="526"/>
<end position="536"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="539"/>
<end position="541"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="545"/>
<end position="553"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="554"/>
<end position="557"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="558"/>
<end position="560"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="562"/>
<end position="564"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="565"/>
<end position="571"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="577"/>
<end position="589"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="595"/>
<end position="598"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="599"/>
<end position="602"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="609"/>
<end position="622"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="625"/>
<end position="638"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="639"/>
<end position="641"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="643"/>
<end position="646"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="648"/>
<end position="657"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="661"/>
<end position="672"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="673"/>
<end position="676"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="678"/>
<end position="680"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="681"/>
<end position="694"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="698"/>
<end position="720"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="721"/>
<end position="725"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="728"/>
<end position="739"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="742"/>
<end position="748"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="749"/>
<end position="753"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="756"/>
<end position="761"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="766"/>
<end position="768"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="774"/>
<end position="776"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="779"/>
<end position="784"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="790"/>
<end position="792"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="795"/>
<end position="805"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="808"/>
<end position="825"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="826"/>
<end position="828"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="838"/>
<end position="842"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="845"/>
<end position="849"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="852"/>
<end position="856"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="857"/>
<end position="861"/>
</location>
</feature>
<feature type="strand" evidence="16">
<location>
<begin position="862"/>
<end position="864"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="865"/>
<end position="867"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="871"/>
<end position="873"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="876"/>
<end position="884"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="887"/>
<end position="889"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="890"/>
<end position="911"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="920"/>
<end position="924"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="929"/>
<end position="931"/>
</location>
</feature>
<feature type="turn" evidence="11">
<location>
<begin position="938"/>
<end position="941"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="942"/>
<end position="945"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="958"/>
<end position="964"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="965"/>
<end position="967"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="969"/>
<end position="971"/>
</location>
</feature>
<feature type="strand" evidence="13">
<location>
<begin position="972"/>
<end position="974"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="975"/>
<end position="993"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="995"/>
<end position="1003"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="1004"/>
<end position="1007"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="1013"/>
<end position="1015"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="1016"/>
<end position="1025"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="1026"/>
<end position="1029"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="1032"/>
<end position="1047"/>
</location>
</feature>
<feature type="strand" evidence="15">
<location>
<begin position="1048"/>
<end position="1050"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1053"/>
<end position="1055"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="1056"/>
<end position="1058"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2RD0"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3HHM"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3HIZ"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3ZIM"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4JPS"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4L1B"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4L23"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4OVU"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4TUU"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4WAF"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4YKN"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5DXH"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5DXT"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5FI4"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5SW8"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5SWG"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5SWP"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5SXA"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5SXB"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P32871"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P42337"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00269"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00877"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00878"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00879"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00880"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15016963"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15289301"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15520168"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15608678"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15712344"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15784156"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15924253"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15930273"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15994075"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16114017"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16322209"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16353168"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16432179"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16533766"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17673550"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18079394"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19805105"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21708979"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22658544"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22729224"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23246288"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23676467"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26593112"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7713498"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000305"/>
<evidence key="52" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="18418043"/>
</source>
</evidence>
<sequence length="1068" mass="124284" checksum="041487231A9A1207" modified="2007-02-20" version="2">
MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQ
LLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFA
IGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKH
IYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLK
LCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMD
CFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGI
YHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHC
PLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWF
SSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPL
SEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAME
LLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTN
QRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILK
QEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLW
LNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLS
IGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRS
CAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDF
LIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIA
YIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>